Palvella Therapeutics Files 8-K
Ticker: PVLA · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1583648
| Field | Detail |
|---|---|
| Company | Palvella Therapeutics, Inc. (PVLA) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, financials, filing
Related Tickers: PIRS
TL;DR
Palvella Therapeutics filed an 8-K, mostly financial docs. Nothing major to see here.
AI Summary
On March 4, 2025, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or disclosures detailed in the provided text.
Why It Matters
This filing indicates routine corporate reporting, likely related to financial statements and exhibits, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any new material risks or significant events.
Key Numbers
- 001-37471 — SEC File Number (Identifies the company's filing history with the SEC.)
- 30-0784346 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- PALVELLA THERAPEUTICS, INC. (company) — Registrant
- Pieris Pharmaceuticals, Inc. (company) — Former company name
- March 4, 2025 (date) — Date of earliest event reported
- 125 Strafford Ave, Suite 360 (location) — Principal executive offices address
- Wayne, Pennsylvania 19087 (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
What was Palvella Therapeutics, Inc. formerly known as?
Palvella Therapeutics, Inc. was formerly known as Pieris Pharmaceuticals, Inc., with a name change effective December 13, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on March 4, 2025.
Where are Palvella Therapeutics, Inc.'s principal executive offices located?
Palvella Therapeutics, Inc.'s principal executive offices are located at 125 Strafford Ave, Suite 360, Wayne, Pennsylvania 19087.
What is the Standard Industrial Classification (SIC) code for Palvella Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Palvella Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding PALVELLA THERAPEUTICS, INC. (PVLA).